

C. DIFFICILE INFECTION (CDI) A VICIOUS CYCLE OF RECURRENCE THAT RESULTS IN A SIGNIFICANT BURDEN^{1,2}

APPROXIMATELY HALF A MILLION CDI CASES
IN THE UNITED STATES ANNUALLY^{2,3}

RECURRENT CDI (rCDI) AFFECTS PATIENT QUALITY OF LIFE
AND HOSPITAL QUALITY METRICS AND REIMBURSEMENT



Recurrence: Up to 35%^{3,4,a}



Re-recurrence: Up to 60%⁵⁻⁹

SIGNIFICANT
COMPLICATIONS
ASSOCIATED WITH CDI



Sepsis: 27%^{10,b}



Colectomy: 7%^{10,b}



Heart failure: 43%⁹



Mortality: 6%³



Mortality in patients with
COVID-19 and CDI: 44%¹¹



Up to 85% of all patients with rCDI
were hospitalized in 12 months¹²



57% of patients with at least one CDI
recurrence experienced ≥ 2 hospital
admissions within 12 months⁹



Hospitalizations average 18 days
for patients with rCDI⁹



84% of patients with
rCDI are readmitted¹²



-\$3K to -\$29K gap exists in
reimbursement per patient¹³



\$131K to \$207K comprised total
cost of a patient with rCDI²

BREAK THE CYCLE



LEARN MORE ABOUT BREAKING THE
CYCLE OF C. DIFF RECURRENCE AT
POWEROFMICROBIOME.COM



Antibiotics are the standard of care for the treatment of *C. diff* and effective for some. However, their use has been shown to disrupt the ecology of the gut microbiome and is a predominant risk factor for CDI recurrence.¹⁴

^aWithin 8 weeks after initial *C. diff* infection diagnosis.³

^bFirst recurrence.¹⁰

References: 1. Centers for Disease Control and Prevention. <https://www.cdc.gov/drugresistance/pdf/threats-report/clostridioides-difficile-508.pdf>. Accessed June 24, 2020. 2. Feuerstadt P, et al. *J Med Econ*. 2020;23(6):603-609. 3. Lessa FC, et al. *N Engl J Med*. 2015;372(9):825-834. 4. Cornely OA, et al. *Clin Infect Dis*. 2012;55(suppl 2):s154-s161. 5. Leong C, Zelenitsky S. *Can J Hosp Pharm*. 2013;66(6):361-368. 6. Kelly CP. *Clin Microbiol Infect*. 2012;18(suppl 6):21-27. 7. Riddle DJ, Dubberke ER. *Infect Dis Clin North Am*. 2009;23(3):727-743. 8. Smits WK, et al. *Nat Rev Dis Primers*. 2016;2:16020. doi:10.1038/nrdp.2016.20. 9. Nelson WW, et al. [published online March 11, 2021]. *J Manag Care Spec Pharm*. 2021;1-11. doi:10.18553/jmcp.2021.20395. 10. Feuerstadt P, et al. *SAGE Open Med*. 2021;9:2050312120986733. doi:10.1177/2050312120986733. 11. Sandhu A, et al. [published online May 22, 2020]. *Emerg Infect Dis*. 2020;26(9):10.3201/eid2609.202126. doi:10.3201/eid2609.202126. 12. Rodrigues R, et al. *Infect Control Hosp Epidemiol*. 2017;38(2):196-202. 13. Zilberberg MD, et al. *Medicine*. 2018;97(36):e12212. doi:10.1097/MD.00000000000012212. 14. McDonald LC, et al. *Clin Infect Dis*. 2018;66(7):e1-e48.



Microbiome
Therapeutics
Development